ASX 200 healthcare share sinks on $2 billion asset sale

Investors are pressuring the healthcare share amid news of a major hospital sale.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare share Ramsay Health Care Ltd (ASX: RHC) is slipping today.

The healthcare stock closed on Friday trading for $53.93 a share. In early trade on Monday, shares are swapping hands for $53.35, down 1.08%.

For some context, the ASX 200 is down 0.19% at this same time.

This comes following news of a multi-billion-dollar hospital asset sale.

What did the ASX 200 healthcare share announce?

ASX 200 investors are pressuring the healthcare share after the company reported it has reached an agreement – together with its partner Sime Darby Holdings Berhad – to sell its 50:50 joint venture in Asia, Ramsay Sime Darby Health Care.

Columbia Asia Healthcare will pay MYR6.06 billion (approximately AU$2 billion) for hospital assets, representing 100% of the joint venture's enterprise value.

Ramsay said it expects to achieve a net profit after tax (NPAT) for its share of the joint venture of around $630 million. This will be reflected in the company's FY 2024 full-year results through the "discontinued operations line".

Management expects pre-tax (post-transaction cost) proceeds of around $935 million. The ASX 200 healthcare share will use the funds to pay down debt. This is expected to result in annualised interest cost savings of $55 million.

FY 2024 net interest costs (including AASB16 lease costs) are now expected to be at the lower end of Ramsay's previously guided range of $570 million to $600 million.

Commenting on the asset sale, Sime Darby CEO Jeffri Salim Davidson said, "While the hospital business is a great asset … the offer from Columbia Asia was one we could not refuse."

Subject to the receipt of regulatory approval from Australia's Foreign Investment Review Board, the sale is expected to be completed by the end of 3Q FY 2024.

Ramsay Health Care share price snapshot

Up 7% over the past month, the ASX 200 healthcare share remains down almost 13% over the past full year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »